Summary of roundtable discussion meeting: Non-human primates to assess risk for EBV-related lymphomas in humans

Journal of Immunotoxicology

Volumn 9, Issue 1, 2012, Pages 121-127

  Kawabata, Thomas ^a   Weaver, James ^b   Thomas, Dolca ^c   Rowe, Martin ^d   Wang, Fred ^e   Kamperschroer, Cris ^a   Haggerty, Helen ^c  

^a PFIZER INC   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Epstein Barr virus; Immunotoxicity; Immunotoxicology; Lymphoma; Monkey; Non human primates

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ANTIVIRAL THERAPY; B LYMPHOCYTE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CLINICAL ASSESSMENT; CLINICAL RESEARCH; CONFERENCE PAPER; DISEASE MARKER; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; HAPLORHINI; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KNOWLEDGE; LYMPHOCRYPTOVIRUS; LYMPHOCYTOTOXICITY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMATE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SCIENCE; SURGICAL PATIENT; T LYMPHOCYTE; VIROGENESIS; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; BIOLOGICAL MARKERS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCRYPTOVIRUS; LYMPHOCYTES; LYMPHOMA; MODELS, ANIMAL; PRIMATES; RISK ASSESSMENT; RISK FACTORS; TOXICITY TESTS; TUMOR VIRUS INFECTIONS; VIRAL LOAD;

HUMAN HERPESVIRUS 4; LYMPHOCRYPTOVIRUS; MACACA FASCICULARIS; PRIMATES;

EID: 84863018272     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2011.635166     Document Type: Conference Paper

References (25)

1. Baecklund E., Iliadou A., Askling J., Ekbom A., Backlin C., Granath F., Catrina A. I., Rosenquist R., Feltelius N., Sundstrom C., and Klareskog L. 2006. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54:692-701.
2. Barton E., Mandal P., and Speck, S. H. 2011. Pathogenesis and host control of gammaherpes-viruses: Lessons from the mouse. Ann. Rev. Immunol. 29:351-397.
3. Benden C., Aurora P., Burch M., Cubitt M., Lloyd C., Whitmore P., Neligan S. L., and Elliott M. J. 2005. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by realtime polyemerase chain reaction. Ped. Transplant. 24:2103-2108. (Pubitemid 41814732)
4. Bonnet F., Jouvencel A. C., Parrens M., Leon M. J., Cotto E., Garrigue I., Morlat P., Beylot J., Fleury H., and Lafon M. E. 2006. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma. J. Clin. Virol. 36:258-263. (Pubitemid 44066893)
5. Doesch A. O., Konstandin M., Celik S., Kristen A., Frankenstein L., Sack F. U., Schnabel P., Schnitzler P., Katus H. A., and Dengle, T. J. 2008. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients. Transplant. Intl. 21:963-971.
6. Fan H., Kim S. C., Chima C. O., Israel B. F., Lawless K. M., Eagan P. A., Elmore S., Moore D. T., Schichman S. A., Swinnen L. J., and Gulley M. L. 2005. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J. Med. Virol. 75:59-69. (Pubitemid 39578791)
7. Feichtinger H., Li S. L., Kaaya E., Putkonen P., Grunewald K., Weyrer K., Bottiger D., Ernberg I., Linde A., Biberfeld G., and Biberfeld, P. 1992. A monkey model for Epstein Barr virus-associated lymphomagenesis in human acquired immunodeficiency syndrome. J. Exp. Med. 176:281-286.
8. Fogg M. H., Garry D., Awad A., Wang F., and Kaur A. 2006. The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques. J. Immunol. 176:3391-3401. (Pubitemid 43363986)
9. Fogg M. H., Kaur A., Cho Y. G., and Wang F. 2005. The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue. J. Virol. 79:12681-12691. (Pubitemid 41433188)
10. Franklin J., Lunt M., Bunn D., Symmones D., and Silman A. 2005. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann. Rheum. Dis. 65:617-622.
11. Gartner B., and Preiksaitis J. K. 2010. EBV viral load detection in clinical virology. J. Clin. Virol. 48:82-90.
12. Gottschalk S., Rooney C. M., and Heslop H. H. 2005. Post-transplant lymphoproliferative disorders. Ann. Rev. Med. 56:29-44. (Pubitemid 40299772)
13. Hislop A. D., Ressing M. E., van Leeuwen D., Pudney V. A., Horst D., Koppers-Lalic D., Croft N. P., Neefjes J. J., Rickinson A. B., and Wiertz E. J. 2007. A CD8+ T-cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J. Exp. Med. 204:1863-1873. (Pubitemid 47236322)
14. Jiang H., Cho Y. G., and Wang F. 2000. Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the rhesus lymphocryptovirus. J. Virol. 74:5921-5932. (Pubitemid 30412961)
15. Lee T. C., Savoldo B., Rooney C. M., Heslop H. E., Gee A. P., Caldwell Y., Barshes N. R., Scott J. D., Bristow L. J., OMahony C. A., and Goss J. A. 2005. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am. J. Transplant. 5:2222-2228. (Pubitemid 41648469)
16. Lunermann J. D., Frey O., Eidner T., Baier M., Roberts S., Sashihara J., Volkmer R., Cohen J. I., Hein G., Kamradt T., and Munz C. 2008. Increased frequency of EBV-specific effector memory CD8+ T-cells correlates with higher viral load in rheumatoid arthritis. J. Immunol. 181:991-1000.
17. McInnes E. F., Jarrett R. F., Langford G., Atkinson C., Horsley J., Goddard M. J., Cozzi E., and Schuurman H. J. 2002. Post-transplant lymphoproliferative disorder associated with primate gammaherpesvirus in cynomolgus monkeys used in pig-to-primate renal xenotransplantation and primate renal allotransplantation. Transplantation 73:44-52. (Pubitemid 34094683)
18. Neovius M., Simard J. F., and Askling J. 2010. Nationwide prevalance of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann. Rheum. Dis. 70:624-629.
19. Oertel S., Trappe R. U., Zeidler K., Babel N., Reinke P., Hummel M., Jonas S., Papp-Vary M., Stubklewe M., Dorken B., Riess H., and Gartner B. 2006. Epstein-Barr viral load in whole blood of adults of post-transplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann. Hematol. 85:478-484. (Pubitemid 44283116)
20. Peng R., Gordadze A. V., Fuentes Panana E. M., Wang F., Zong J., Hayward G. S., Tan J., and Ling P. D. 2000. Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses. J. Virol. 74:379-389. (Pubitemid 30002919)
21. Rivaille, P., Carville A., Kaur A., Rao P., Quink C., Kutok J. L., Westmoreland S., Klumpp S., Simon M., Aster J. C., and Wang F. 2004. Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: An animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host. Blood 104:1482-1489. (Pubitemid 39166528)
22. Schmidtko J., Wang R., Wu C. L., Mauiyyedi S., Harris N. L., Della Pelle P., Brousaides N., Zagachin L., Ferry J. A., Wang F., Kawai T., Sachs D. H., Cosimi B. A., and Colvin R. B. 2002. Post-transplant lymphoproliferative disorder associated with an Epstein- Barr-related virus in cynomolgus monkeys. Transplantation 73:1431-1439. (Pubitemid 34547464)
23. Sebelin-Wulf K., Nguyem T. D., Oertel S., Papp-Vary M., Trappe R. U., Schulzki A., Pezzutto A., Riess H., and Subklewe M. 2007. Quantitative analysis of EBV-specific CD4/CD8 T-cell numbers, absolute CD4/CD8 T-cell numbers and EBV load in solid organ transplant recipients with PLTD. Transplant. Immunol.17:203-210.
24. Smets F., Latinne D., Bazin H., Reding R., Otte J. B., Buts J. P., and Sokal E. M. 2002. Ratio between Epstein-Barr viral load and anti- Epstein-Barr virus-specific T-cell response as a predictive marker of post-transplant lymphoproliferative disease. Transplantation 73:1603-1610. (Pubitemid 34568673)
25. Wolfe F. and Michaud K. 2004. Lymphoma in rheumatoid arthritis. The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 Patients. Arthritis Rheum. 50:1740-1751. (Pubitemid 38725085)